4
Changes in Ownership
AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-26-000036
Chief Commercial Officer sold 2,868 shares at $28.96 ($83,057)
- Chief Commercial Officer acquired 9,666 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Milanova Tsveta · Chief Commercial Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-03-02 | Exercise or conversion : show line 1 in the form 10b5-1 | +5,666 | 40,459 | D | ||
| 2026-03-02 | Sale : show line 2 in the form 10b5-1 | −1,681 | $28.96 | $48,682 | 38,778 | D |
| 2026-03-02 | Exercise or conversion : show line 3 in the form 10b5-1 | +4,000 | 42,778 | D | ||
| 2026-03-02 | Sale : show line 4 in the form 10b5-1 | −1,187 | $28.96 | $34,376 | 41,591 | D |
| Open-market sales · 2,868 sh · avg $28.96 · $83,057 | ||||||
Table II: Derivative
4 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-03-01 | Grant or award : show line 5 in the form 10b5-1 Restricted stock units | +14,000 | 14,000 | D |
| 2026-03-01 | Grant or award : show line 6 in the form 10b5-1 Stock options (right to buy) | +52,000 | 52,000 | D |
| 2026-03-02 | Exercise or conversion : show line 7 in the form 10b5-1 Restricted stock units | −5,666 | 5,667 | D |
| 2026-03-02 | Exercise or conversion : show line 8 in the form 10b5-1 Restricted stock units | −4,000 | 8,000 | D |
Loading xslF345X05/wk-form4_1772572436.xml…